Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma

JAMA Oncol. 2020 Aug 1;6(8):1297-1299. doi: 10.1001/jamaoncol.2020.1641.

Authors

Jason M Scovell^{1

2}, Karl Benz³, Iryna Samarska⁴, Taylor P Kohn³, Jody E Hooper⁴, Andres Matoso⁴, Amin S Herati³

Affiliations

¹ Scott Department of Urology, Baylor College of Medicine, Houston, Texas.
² Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
³ James Buchanan Brady Urological Institutions, The Johns Hopkins Medical Institutions, Baltimore, Maryland.
⁴ Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland.

Abstract

This cohort study examines the potential association of the use of immune checkpoint inhibitors with testicular histopathologic conditions.

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / adverse effects
Humans
Immune Checkpoint Inhibitors / adverse effects*
Ipilimumab / adverse effects
Male
Melanoma / drug therapy*
Middle Aged
Nivolumab / adverse effects
Spermatogenesis / drug effects*
Testis / drug effects
Testis / pathology
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
Ipilimumab
Nivolumab
pembrolizumab